Medisana AG intended to increase the company's share capital with two capital measures and to issue own shares on the market. Heuking Kühn Lüer Wojtek legally advised the company.
In detail, a capital increase results from issuing 210,000 new bearer shares with exclusion of the subscription right, and an additional capital increase with subscription by issuing up to 2,250,000 bearer shares. In parallel, up to 630,000 own shares will be placed on the market. Investors have already been found for the 840,000 shares from the two measures without subscription right (capital increase with exclusion of subscription right and the sale of own shares). For the capital increase with subscription right, up to 2,250,000 new shares, entitled to dividends from January 1, 2013, will be offered to the shareholders in a ratio of 3:1 (three existing shares entitle to the purchase of one new share). There will be no public trading of subscription rights. Non-exercised subscription rights will be derecognized upon expiry of the subscription period. Shareholders may also exercise an oversubscription right.
The company expects a capital inflow of about EUR 6.7 million from the overall measure and a new share capital of EUR 10,890,327. With this liquidity, the company intends to finance its future investments.
Heuking Kühn Lüer Wojtek has advised Medisana AG already since 2010, including on a product introduction and on the takeover of Gimelli Laboratories Ltd.
Responsible for the project
Heuking Kühn Lüer Wojtek:
Dr. Thorsten Kuthe,
Madeleine Zipperle (both Capital Markets), both Cologne